Literature DB >> 28542929

The immune response to Prevotella bacteria in chronic inflammatory disease.

Jeppe Madura Larsen1,2.   

Abstract

The microbiota plays a central role in human health and disease by shaping immune development, immune responses and metabolism, and by protecting from invading pathogens. Technical advances that allow comprehensive characterization of microbial communities by genetic sequencing have sparked the hunt for disease-modulating bacteria. Emerging studies in humans have linked the increased abundance of Prevotella species at mucosal sites to localized and systemic disease, including periodontitis, bacterial vaginosis, rheumatoid arthritis, metabolic disorders and low-grade systemic inflammation. Intriguingly, Prevotella abundance is reduced within the lung microbiota of patients with asthma and chronic obstructive pulmonary disease. Increased Prevotella abundance is associated with augmented T helper type 17 (Th17) -mediated mucosal inflammation, which is in line with the marked capacity of Prevotella in driving Th17 immune responses in vitro. Studies indicate that Prevotella predominantly activate Toll-like receptor 2, leading to production of Th17-polarizing cytokines by antigen-presenting cells, including interleukin-23 (IL-23) and IL-1. Furthermore, Prevotella stimulate epithelial cells to produce IL-8, IL-6 and CCL20, which can promote mucosal Th17 immune responses and neutrophil recruitment. Prevotella-mediated mucosal inflammation leads to systemic dissemination of inflammatory mediators, bacteria and bacterial products, which in turn may affect systemic disease outcomes. Studies in mice support a causal role of Prevotella as colonization experiments promote clinical and inflammatory features of human disease. When compared with strict commensal bacteria, Prevotella exhibit increased inflammatory properties, as demonstrated by augmented release of inflammatory mediators from immune cells and various stromal cells. These findings indicate that some Prevotella strains may be clinically important pathobionts that can participate in human disease by promoting chronic inflammation.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  Prevotella; T cells; cytokines; inflammation; inflammatory disease; mucosa

Mesh:

Substances:

Year:  2017        PMID: 28542929      PMCID: PMC5506432          DOI: 10.1111/imm.12760

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  102 in total

Review 1.  Inflammatory and immune pathways in the pathogenesis of periodontal disease.

Authors:  Ali Cekici; Alpdogan Kantarci; Hatice Hasturk; Thomas E Van Dyke
Journal:  Periodontol 2000       Date:  2014-02       Impact factor: 7.589

Review 2.  Microbiology in the post-genomic era.

Authors:  Duccio Medini; Davide Serruto; Julian Parkhill; David A Relman; Claudio Donati; Richard Moxon; Stanley Falkow; Rino Rappuoli
Journal:  Nat Rev Microbiol       Date:  2008-05-13       Impact factor: 60.633

3.  A metagenome-wide association study of gut microbiota in type 2 diabetes.

Authors:  Junjie Qin; Yingrui Li; Zhiming Cai; Shenghui Li; Jianfeng Zhu; Fan Zhang; Suisha Liang; Wenwei Zhang; Yuanlin Guan; Dongqian Shen; Yangqing Peng; Dongya Zhang; Zhuye Jie; Wenxian Wu; Youwen Qin; Wenbin Xue; Junhua Li; Lingchuan Han; Donghui Lu; Peixian Wu; Yali Dai; Xiaojuan Sun; Zesong Li; Aifa Tang; Shilong Zhong; Xiaoping Li; Weineng Chen; Ran Xu; Mingbang Wang; Qiang Feng; Meihua Gong; Jing Yu; Yanyan Zhang; Ming Zhang; Torben Hansen; Gaston Sanchez; Jeroen Raes; Gwen Falony; Shujiro Okuda; Mathieu Almeida; Emmanuelle LeChatelier; Pierre Renault; Nicolas Pons; Jean-Michel Batto; Zhaoxi Zhang; Hua Chen; Ruifu Yang; Weimou Zheng; Songgang Li; Huanming Yang; Jian Wang; S Dusko Ehrlich; Rasmus Nielsen; Oluf Pedersen; Karsten Kristiansen; Jun Wang
Journal:  Nature       Date:  2012-09-26       Impact factor: 49.962

4.  Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals.

Authors:  J F Vázquez-Castellanos; S Serrano-Villar; A Latorre; A Artacho; M L Ferrús; N Madrid; A Vallejo; T Sainz; J Martínez-Botas; S Ferrando-Martínez; M Vera; F Dronda; M Leal; J Del Romero; S Moreno; V Estrada; M J Gosalbes; A Moya
Journal:  Mucosal Immunol       Date:  2014-11-19       Impact factor: 7.313

Review 5.  Anaerobic infections: update on treatment considerations.

Authors:  Elisabeth Nagy
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

Review 6.  Update on the taxonomy and the clinical and laboratory characteristics of pigmented anaerobic gram-negative rods.

Authors:  H R Jousimies-Somer
Journal:  Clin Infect Dis       Date:  1995-06       Impact factor: 9.079

7.  Chronic obstructive pulmonary disease and asthma-associated Proteobacteria, but not commensal Prevotella spp., promote Toll-like receptor 2-independent lung inflammation and pathology.

Authors:  Jeppe M Larsen; Hanieh S Musavian; Tariq M Butt; Camilla Ingvorsen; Anna H Thysen; Susanne Brix
Journal:  Immunology       Date:  2015-02       Impact factor: 7.397

8.  Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease.

Authors:  Eliseo Papa; Michael Docktor; Christopher Smillie; Sarah Weber; Sarah P Preheim; Dirk Gevers; Georgia Giannoukos; Dawn Ciulla; Diana Tabbaa; Jay Ingram; David B Schauer; Doyle V Ward; Joshua R Korzenik; Ramnik J Xavier; Athos Bousvaros; Eric J Alm
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

9.  Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment.

Authors:  Xochitl C Morgan; Timothy L Tickle; Harry Sokol; Dirk Gevers; Kathryn L Devaney; Doyle V Ward; Joshua A Reyes; Samir A Shah; Neal LeLeiko; Scott B Snapper; Athos Bousvaros; Joshua Korzenik; Bruce E Sands; Ramnik J Xavier; Curtis Huttenhower
Journal:  Genome Biol       Date:  2012-04-16       Impact factor: 13.583

10.  Microbial communities in the upper respiratory tract of patients with asthma and chronic obstructive pulmonary disease.

Authors:  HeeKuk Park; Jong Wook Shin; Sang-Gue Park; Wonyong Kim
Journal:  PLoS One       Date:  2014-10-16       Impact factor: 3.240

View more
  266 in total

Review 1.  Research progress on gut microbiota in patients with gastric cancer, esophageal cancer, and small intestine cancer.

Authors:  Changchang Chen; Linjie Chen; Lijun Lin; Dazhi Jin; Yaoqiang Du; Jianxin Lyu
Journal:  Appl Microbiol Biotechnol       Date:  2021-05-26       Impact factor: 4.813

2.  Intestinal and hepatic microbiota changes associated with chronic ethanol administration in mice.

Authors:  Sena Bluemel; Lirui Wang; Claire Kuelbs; Kelvin Moncera; Manolito Torralba; Harinder Singh; Derrick E Fouts; Bernd Schnabl
Journal:  Gut Microbes       Date:  2019-04-14

Review 3.  Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes.

Authors:  Yasaman Ghorbani; Katherine J P Schwenger; Johane P Allard
Journal:  Eur J Nutr       Date:  2021-03-02       Impact factor: 5.614

Review 4.  Gastrointestinal tract microbiota modifications in systemic sclerosis.

Authors:  Elizabeth R Volkmann; Anna-Maria Hoffmann-Vold
Journal:  Eur J Rheumatol       Date:  2019-12-19

Review 5.  The microbiome and HIV persistence: implications for viral remission and cure.

Authors:  Wei Li A Koay; Lilly V Siems; Deborah Persaud
Journal:  Curr Opin HIV AIDS       Date:  2018-01       Impact factor: 4.283

Review 6.  The "Gut Feeling": Breaking Down the Role of Gut Microbiome in Multiple Sclerosis.

Authors:  Samantha N Freedman; Shailesh K Shahi; Ashutosh K Mangalam
Journal:  Neurotherapeutics       Date:  2018-01       Impact factor: 7.620

7.  The nasal microbiome in asthma.

Authors:  Mina Fazlollahi; Tricia D Lee; Jade Andrade; Kasopefoluwa Oguntuyo; Yoojin Chun; Galina Grishina; Alexander Grishin; Supinda Bunyavanich
Journal:  J Allergy Clin Immunol       Date:  2018-03-05       Impact factor: 10.793

Review 8.  Autoimmunity, inflammation, and dysbiosis mutually govern the transition from the preclinical to the clinical stage of rheumatoid arthritis.

Authors:  Alexander Kalinkovich; Gulzan Gabdulina; Gregory Livshits
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

Review 9.  The Oral Microbiota Is Modified by Systemic Diseases.

Authors:  D T Graves; J D Corrêa; T A Silva
Journal:  J Dent Res       Date:  2018-10-25       Impact factor: 6.116

10.  Combination Antibiotics Improves Disease Activity and Alters Microbial Communities in Children With Ulcerative Colitis.

Authors:  Kattayoun Kordy; Anna Claudia Romeo; David J Lee; Fan Li; Sara Zabih; Monica Saavedra; Nicole J Cunningham; Nicole Tobin; Grace M Aldrovandi
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-09       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.